Meanwhile, Eli Lilly is waving its torch at Sun Pharmaceuticals to keep the Indian drug maker away from ADHD drug Strattera. The company has already been fighting off two other companies intent on duplicating the drug: Sandoz, Novartis' generics unit; and Actavis Group.
Strattera generated $282 million in sales during the first half of this year.
- read this article [1] from India's Economic Times
Related Articles:
Lilly beset by potential Strattera imitators. Report [2]
Feds to study ADHD drugs for heart risks. Report [3]
Lilly developing biotech drugs the old-fashioned way. Report [4]
Links:
[1] http://economictimes.indiatimes.com/News/News_By_Industry/Healthcare__Biotech/US_firm_drags_Sun_Pharma_to_court_on_Strattera/articleshow/2399679.cms
[2] http://www.fiercepharma.com/story/lilly-beset-potential-strattera-imitators/2007-08-31
[3] http://www.fiercepharma.com/story/feds-study-adhd-drugs-heart-risks/2007-09-18
[4] http://www.fiercebiotech.com/story/lilly-developing-biotech-drugs-old-fashioned-way/2007-07-31